



ASX & Media Release

## Completion of Placement

**Melbourne, Australia; May 23, 2018:** Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that it has successfully completed the Placement as announced on 16 May 2018 and 21 May 2018, raising a total of \$4.6 million (before costs) to institutional and sophisticated investors and strategic investors.

Somers and Partners Pty Ltd acted as lead manager to the Placement.

Funds raised will be used to accelerate the development of Patrys' Deoxymab platform, with a range of new pre-clinical studies planned to create shareholder value by supporting business development efforts, as well as corporate activities including insurance claim prosecution.

**-Ends-**

**For further information, please contact:**

Patrys Limited:  
James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:  
Ben Walsh  
WE Buchan  
P: +61 2 9237 2801  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).